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Translational relevance 
Besides the promotion of malignant behavior, tumor hypoxia induces brittle vasculature that 
impedes the efficient delivery of chemotherapeutic agents. Inositol trispyrophosphate (ITPP) is 
a novel antihypoxic compound known to inhibit the hypoxic tumor response and to improve 
drug delivery if given concomitantly. More so, ITPP lacks significant toxicity and hence may 
effectively be used in the clinic for the improvement of existing treatments. Here, we provide 
important, but currently lacking data to inform future phase II/III trials on ITPP. We illustrate 
the main working mode of ITPP, show that the antihypoxic/vascular effects of ITPP are 
sustained, and demonstrate the superiority of ITPP in potentiating subsequent chemotherapy 
effects. Acting as a direct inhibitor of tumor hypoxia, ITPP treatment generates a time window 
that can be exploited to enhance existing chemotherapy regimens. A phase Ib/IIa trial is 
currently assessing the safety of ITPP in cancer patients.  
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Abstract 
Purpose. Tumor hypoxia activates hypoxia-inducible factors (Hifs), which induce a range of 
malignant changes including vascular abnormalities. Here we determine whether inhibition of 
the hypoxic tumor response through myo-inositol trispyrophosphate (ITPP), a compound with 
antihypoxic properties, is able to cause prolonged vascular normalization that can be exploited 
to improve standard of care treatment.   
Experimental design. We tested ITPP on two syngeneic orthotopic mouse models of lethal 
colorectal (CRC) liver metastasis. Tumors were monitored by MRI and analyzed for the 
hypoxic response and their malignant potential. A Hif activator and in vitro assays were used to 
define the working mode of ITPP. Hypoxic response and vasculature were re-evaluated four 
weeks after treatment. Finally, we determined survival following ITPP monotherapy, FOLFOX 
monotherapy, FOLFOX plus Vegf antibody, and FOLFOX plus ITPP, both overlapping and 
sequential.   
Results. ITPP reduced tumor load, efficiently inhibited the hypoxic response, and improved 
survival. These effects were lost when mice were pretreated with a Hif activator. Its immediate 
effects on the hypoxic response, including an apparent normalization of tumor vasculature, 
persisted for at least four weeks after treatment cessation. Compared to FOLFOX alone, Vegf 
antibody combined with FOLFOX prolonged survival by <30%, whereas ITPP combined with 
FOLFOX extended survival by >140%, regardless of whether FOLFOX was given in overlap or 
after ITPP exposure.  
Conclusions. Our findings reveal a truly antihypoxic mechanism for ITPP and demonstrate the 
capacity of this nontoxic compound to potentiate the efficacy of existing anticancer treatment in 
a way amenable to clinical translation.  
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Introduction 
Tumor hypoxia activates the hypoxia-inducible factors (Hifs), which induce an adaptive 
response associated with an array of processes that foster tumor progression (1-4). Most famous 
is the angiogenic switch, leading to the formation of immature, leaky vessels that however 
cannot re-install normoxia but instead enhance the spread of disease (5). Vascular normalization 
- the reversal to a more physiological network of mature and tight vessels - is a goal aspired by 
modern therapies, particularly because it also promotes the delivery and efficacy of anticancer 
compounds (5). However, hypoxia drives many other processes, including changes in energy 
metabolism (Warburg effect), chronic inflammation, suppression of adaptive immunity, 
invasive behavior, or an increased tumorigenic potential (6-10). Considering this complexity, 
the arguably simplest approach to normalize vessels and combat malignant behavior is the 
targeting of hypoxia per se.  
Myo-inositol trispyrophosphate (ITPP) is a novel molecule that combines the necessary 
features for the successful treatment of tumor hypoxia (11). Acting as an allosteric effector of 
hemoglobin, ITPP increases dissociation of O2 from heme particularly under low pO2, creating 
antihypoxic potency (11). Additionally, its uptake seems to be tissue-specific towards 
erythrocytes (12). More so, ITPP does display little, if any, in vivo toxicity, neither in animals 
(13-16) nor humans (http://normoxys.com/clinical-trial-results/). In preclinical studies, ITPP 
markedly improved outcomes in hepatoma, colorectal cancer (CRC), breast cancer, melanoma, 
and pancreatic cancer (13-16). Combined evidence from these studies indicates ITPP restores 
tumor normoxia, downregulates Hif/Vegf, and inhibits processes associated with the hypoxic 
response. Notably, clear signs of vascular normalization were likewise reported. Owing to the 
improvements in vessel structure, ITPP strongly potentiated the effects of gemcitabine in a 
syngeneic model of pancreatic cancer (15, 16). 
Despite these impressive effects, several questions remain open before exploring ITPP in 
human cancer. Although the working mode of ITPP seemingly relies on the regain of tumor 
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normoxia and the subsequent stalling of the hypoxic response, a formal prove for this is lacking 
and direct effects on cancer cells remain possible (15, 16).  The potentiation of cytotoxic 
chemotherapy through ITPP was shown in the setting of concomitant application (15, 16). In 
clinical practice however, sequential (chemotherapy follows ITPP treatment) rather than 
concomitant application would be more feasible both in terms of ethical concerns and toxicity 
control. Likewise, how the combination of ITPP with chemotherapy will perform against 
current combination approaches that consider vascular normalization (i.e. anti-angiogenic 
therapy) is unknown.  
Here, we tested ITPP on two syngeneic orthotopic mouse models of CRC liver metastasis, 
the most frequent cause of death due to CRC (17). Our experiments were designed to i) clarify 
the working mode of ITPP, to ii) establish a time window associated with vascular 
normalization through ITPP, and to iii) estimate the clinical efficacy of ITPP-enhanced 
chemotherapy by comparing with the current standard FOLFOX plus neutralizing Vegf 
antibody.  
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Methods 
Animals 
All animal experiments were in accord with Swiss Federal Animal Regulations and 
approved by the Veterinary Office of Zurich. Male mice (C57Bl/6 and BALB/c, from Harlan. 
Itingen, Switzerland) aged 10-12 weeks were kept on a 12-hour day/night cycle with free access 
to food and water.  
 
Animal Procedures, Treatment, and MRI Imaging  
Selective portal vein injection was used for the generation of CRC liver metastasis, with 
concurrent clamping of distal liver lobes leading to tumor development restricted to the right 
and caudate lobes. Thereby, survival mainly depends on the cancer development within affected 
lobes (manuscript under revision). ITPP was synthesized as previously described (11) and 
administered as a solution containing calcium chloride to balance its chelating effects (13). 
ITPP was injected i.v. five times every 48h in a volume of 100 µl at 500mg/kg (Fig. 1A). 
Controls received saline. DMOG (BML-EI347-0050, Enzo Life Science, Farmingdale, New 
York; 40 mg/kg in 100 µl saline) was i.v. injected 4h before every ITPP injection (18). 
FOLFOX (6 mg/kg oxaliplatin, followed 2h later by 90 mg/kg folinic acid and 50 mg/kg 5-
fluorouracil, Sigma-Aldrich, Dorset, UK) was given 5x every other day either alone for 
monotherpay (akin to ITPP, Fig. 1A), or 24h following ITPP administration (overlapping mode) 
or 24h after the last ITPP dose (sequential mode) for combination therapy (19). Controls 
received saline. Anti-Vegf antibody or control IgG (4 µg/kg, R&D Systems, Abingdon UK) 
were injected i.v. concomitant with FOLFOX as described (20). MRI was performed on a 
Bruker Biospin 4.7 Tesla imager (Ettlingen, Germany) at the day 7, 17, 45, or at time of death 
in the survival studies. 
 
Blood oxygen saturation 
Oxygen dissociation curves (P50 values) were determined with a HEMOX Analyzer (TCS 
Scientific, New Hope, PA). The percentage of O2 hemoglobin saturation was continuously 
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recorded in 50 μL blood mixed with 3 mL Hemox buffer and 10 μL anti-foaming agent 
equilibrated at 37°C. Chart software (AD Instruments, Colorado Springs, USA) was used for 
analysis (13). 
 
Cell culture and ex vivo experiments 
Syngeneic CRC cells MC-38 (C57Bl/6 background, a kind gift from Carole Bourquin) and 
CT-26 (BALB/c background, LGC Promochem, Molsheim, France) were cultured as reported 
(21). Freshly resected tumors were sequentially minced through a 100µm and a 30µm mesh  
(BD Falcon
TM
, Franklin Lakes, NJ) into single cells. Invasion assays were performed using 8µm 
pore cell culture inserts and Matrigel (BD Falcon
TM
) as described (22). For s.c. injections, 100 
µl of single cell preparation from resected tumors at 5x10
6
 cells/ml in PBS were used. Glucose 
and lactate levels were determined with a Fuji Dri-Chemi 4000i (Fujifilm Corporation, Tokyo, 
Japan). All in vitro experiments were performed in triplicates. 
 
Histological assessment 
Hematoxylin-Eosine staining was performed on 3µm archived liver sections. For 
immunohistochemistry, antigens were retrieved by boiling in citrate buffer. Secondary detection 
was done using the Ventana Discovery automated staining system and the iView DAB kit 
(Ventana Medical Systems, Tucson, AZ). See Supplements for primary antibodies.   
 
Real-Time Polymerase Chain Reaction, Western blots, ELISA 
qRT-PCR and immunoblots were performed as described (20). See Supplements for further 
information.   
 
Statistical Analysis 
At least six animals/group were analyzed unless specified otherwise. Differences between 
the groups were assessed by a 2-tailed t test assuming unequal variance, or by one-way analysis 
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of variance where applicable. Statistical significance was set at p<0.05, with data presented as 
means and 95% confidence intervals. Prism 5.0 (GraphPad, San Diego, CA) software was used.  
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Results 
Impact of ITPP on tumor development 
The impact of ITPP was tested on two syngeneic orthotopic models of CRC liver 
metastasis (MC-38 and CT-26 CRC cells injected into the portal vein of C57BL/6 and BALB/c 
mice, respectively). These models feature tumors restricted to the right and caudate liver lobes, 
with survival largely dependent on the intralobular tumor development (manuscript under 
revision).  
ITPP treatment (Supplementary Fig. 1A) was started after tumor diagnosis by MRI at day 7 
and was repeated five times every other day (Fig. 1A). After treatment (day 17), tumors were 
harvested and analyzed (Fig. 1B). Compared to saline-treated tumors, ITPP-treated tumors 
displayed reduced proliferative activity, increased apoptosis, and decreased DAMP levels. 
Likewise, ITPP treatment reduced both the number and volume of tumors per animal (Fig. 1B, 
Supplementary Fig. 2A).  
 
Impact of ITPP on tumor hypoxia and animal survival 
The impact of ITPP on tumor hypoxia was assessed through Hif expression and 
pimonidazole staining. In both tumor models, ITPP led to nuclear downregulation of Hif1a and 
Hif2a compared to controls. Likewise, pimonidazole staining indicated a strong reduction in 
hypoxic tumor areas through ITPP (Fig. 1C, Supplementary Fig. 2B). Since hypoxia/HIF1a can 
predict outcome in metastatic CRC (2-4), we examined survival of tumor-bearing mice. ITPP 
prolonged survival by 50% (MC-38/B6 model, Fig. 1D, median survival (±95%CI) from 
treatment end: 37.8±2.09 days for controls and 56.7±3.61 days for ITPP-treated animals) and 
45% (CT-26/BALB model, Supplementary Fig. 2C, survival 37.1±2.42 days for controls and 
53.9±2.54 days for ITPP-treated animals) relative to controls, with animals dying from portal 
congestion due to tumor growth. Therefore, the anti-hypoxic and growth inhibitory actions of 
ITPP are associated with an improved outcome.  
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Impact of ITPP on the hypoxic tumor response 
To demonstrate inhibition of the hypoxic response by ITPP, we assessed a series of 
markers related to hypoxia-driven processes. Overall, ITPP-treatment was associated with the 
inhibition of the Warburg effect (a shift from glycolysis to -oxidation, Fig. 2A, Supplementary 
Fig. 3A), with reduced inflammation, and the increased influx of immune cells (Fig. 2B, 
Supplementary Fig. 3B). Increased macrophage infiltration was associated with M1 polarization 
marker expression, consistent with an anticancerous phenotype (23). Additionally, we observed 
in ITPP-treated relative to control tumors downregulation of markers of the epithelial-
mesenchymal transition (EMT) (9) along with congruent changes in cancer cell morphology 
(Fig. 3A/B, Supplementary Fig. 4A/B), and in sera from ITPP-treated mice a relative reduction 
in tumor-independent, systemic promoters of malignancy (Fig. 3C, Supplementary Fig. 4B), 
which typically are induced by hypoxia-associated inflammation (24).  
To substantiate the novel finding of a reduced malignant potential following ITPP 
treatment, we isolated on day 17 cancer cells from our MC-38/B6 model and assessed their ex 
vivo invasiveness. Relative to cells from control tumors, the invasion of ITPP-exposed cancer 
cells through Matrigel was reduced by >50% (Fig. 3D). Moreover, when ex vivo cancer cells 
were s.c. injected into recipient mice, cells from control tumors formed nearly 3x larger tumors 
than cells from ITPP tumors (Fig. 3E), indicating that ITPP reduces both invasiveness and 
tumorigenic potential. Together, these findings indicate ITPP efficiently inhibits the hypoxic 
response in experimental liver metastasis.  
 
Dependency of ITPP action on hypoxia-inducible factors 
ITPP may inhibit the hypoxic response via Hif downregulation. If so, exogenous activation 
of Hifs should counteract its effects. Tumor-bearing mice (MC-38/B6) were injected with ITPP 
or saline and co-treated or not with the generic Hif activator dimethyloxaloylglycine (DMOG) 
(25). In both saline and ITPP treated tumors, DMOG promoted all parameters positively related 
to the hypoxic response. Vice versa, ITPP antagonized these changes in vehicle- or DMOG-
exposed tumors. Notably, ITPP effects appeared to be neutralized by the addition of DMOG 
 11 
(Fig. 4A-C). Indeed, while survival was prolonged in the ITPP group (65.5±2.79 days versus 
35.5±3.03 for controls), survival in the ITPP plus DMOG group (41.5±2.98) was similar to 
saline controls. The DMOG group (27.5±2.81) tended to have the worst outcome (Fig. 4D). We 
conclude that the inhibition of Hifs is a main action mechanism underlying the anti-cancerous 
properties of ITPP.  
 
Direct effects of hypoxia and ITPP on cancer cells 
ITPP might modulate Hifs via hypoxia-independent mechanisms. To clarify, we exposed 
hypoxic MC-38 and CT-26 cultures to normoxia and examined aspects of the hypoxic response. 
Similar to ITPP in vivo, normoxia in vitro reduced growth, counteracted the Warburg effect 
(increased mitochondrial, reduced glycolytic activity), and inhibited invasiveness of cancer cells 
(Supplementary Fig. 5A-C). In contrast, the addition of ITPP to hypoxic cultures had no impact 
on investigated parameters (Supplementary Fig. 5D-F). Therefore, the ITPP effects on tumors 
are indirect, can be mimicked through normoxia, are dependent on Hif inhibition, and 
consequently must be mediated by the inhibition of hypoxia.  
 
Impact of ITPP on tumor-associated vascular normalization 
ITPP downregulates angiogenic molecules, including Vegf and Plgf (5, 24, 26) (Fig. 4C, 
Supplementary Fig. 4B). On histology, the density of Cd31/34-positive vessels was visibly 
reduced in ITPP-treated versus control tumors. Vice versa, the density of vessels positive for 
Notch1 and VE-cadherin, both central for the maintenance of a mature and tight vessel 
phenotype (27-31), was increased in ITPP-treated tumors (Supplementary Figs. 6 & 7). 
Therefore, ITPP treatment of tumors is associated with vascular normalization.  
 
Long-term impact of ITPP on the hypoxic tumor response 
The observed endothelial changes are consistent with a functional vascular normalization 
through ITPP, as has been reported for other preclinical models (15, 16). If ITPP-induced vessel 
normalization is functional also in our CRC metastasis model, suppression of the hypoxic 
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response should be long-lasting. We analyzed tissue/serum from tumor-laden mice at four 
weeks after treatment (day 45, before controls start to die) and compared with the time 
immediately after treatment (day 17). The hypoxic response was assessed through Hif1a, Hif2a 
& Vegfa and markers related to glycolysis (Slc2a, Ldha), mitochondrial mass (Cox4i1), -
oxidation (Cpt1a, Hadha, Hadhb), mitochondrial dynamics (Fis1, Drp1, Mfn2, Opa1), 
inflammation (Tnfa, Il6, Emr1), macrophage polarization (Cd40, Nos2a, Arg1, Mrc1, Mgl1), the 
EMT (Twist1, Snai1, Src, Vim, Ocln, Cdh1), angiogenesis (Vegf, Plgf), necrosis/inflammation 
(Hmgb1), and systemic tumor promotion (Scf, osteopontin, Cxcl12). Comparison of time points 
revealed ITPP treatment induces similar qualitative and quantitative changes at day 17 and 45 
(Fig. 5A, Supplementary Fig. 8A), indicating a long-range stalling of the hypoxic response 
through ITPP. Re-examination of endothelial proteins indicated the persistence of a reduced 
Cd31/34-microvessel density along with an increase in mature vessels at four weeks after ITPP 
treatment (Fig. 5B, Supplementary Fig. 8B). We conclude that ITPP induces a stable, long-
lasting tumor response which is accompanied by vascular normalization.  
 
Impact of ITPP on cytotoxic chemotherapy in comparison to anti-angiogenic therapy 
The ITPP effects on tumor-associated vasculature are expected to improve the delivery and 
efficacy of cytotoxic regimens (16). The FOLFOX regimen is a standard for metastatic CRC, 
and nowadays often is combined with antiangiogenic VEGF antibody (32-34). To determine 
whether ITPP may improve the effects of FOLFOX, we treated tumor-bearing mice (MC-
38/B6) with ITPP, the drugs of the FOLFOX regimen (here referred to as FOLFOX), or a 
combination thereof. To estimate the potential clinical efficacy, we compared to FOLFOX plus 
neutralizing anti-mouse Vegf antibody (Fig. 6A). Compared to controls (median survival from 
treatment end = 35.5±3.03 [days±95%CI]), FOLFOX extended survival by 75% [62±3.03], akin 
to ITPP monotherapy [65.5±2.79](Fig. 8A). When combined with Vegf antibody, FOLFOX 
prolonged survival by 225% [80±2.55]. However, when combined with ITPP (overlapping 
mode), survival was extended by 431% [153±3.34], indicating synergistic efficacy (p<0.001 
when comparing additive effects of FOLFOX and ITPP monotherapy with combination 
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treatment). Importantly, a similar (428%) survival advantage [152±4.17] was achieved when 
FOLFOX was given after ITPP treatment (sequential mode, p<0.001 for comparing additive 
effects with combination), consistent with a lasting effect of ITPP on vasculature.   
When assessing tumor load, only small differences were noted between the different 
treatments regarding tumor volume (Fig. 6B/C). ITPP alone or with FOLFOX however had the 
strongest impact on tumor multiplicity, an effect that persisted until death. Altogether, these 
findings demonstrate a marked potency of ITPP to enhance classic chemotherapy well beyond 
the efficacy of standard-of-care treatments.  
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Discussion 
In this study, we demonstrate that the effects of ITPP on experimental liver metastases rely 
on the inhibition of the hypoxic response via Hif downregulation secondary to the restoration of 
tumor normoxia. Furthermore, we show that the inhibition of the hypoxic response is sustained 
and associated with vascular normalization, providing a generous window of therapeutic 
opportunity. Consequent to this lasting response, ITPP potentiates cytotoxic chemotherapy 
given in overlapping or sequential mode, pointing to the functionality of prolonged vascular 
normalization and resulting in a marked survival advantage when compared to chemotherapy 
alone or combined with an antiangiogenic agent.  
In keeping with previous studies (13-16), ITPP treatment of mice carrying syngeneic 
orthotopic CRC liver metastases reduced tumor load, inhibited hypoxia, Hifs, the hypoxic 
response, promoted vessel normalization, and improved survival.  Novel findings include the 
increased influx of macrophages with M1 polarization expression profiles, a change that may 
result from the ITPP-associated drop in Plgf (35) and may directly promote vessel 
normalization (36). Furthermore, we provide functional evidence for the inhibition of a 
malignant phenotype through ITPP, in terms of both invasiveness and colony-forming capacity. 
A general reduction in malignant potential was underscored by the downregulation of tumor-
independent metastatic promoters, consistent with a systemic action of ITPP.  
The ability of ITPP to suppress the hypoxic response is the upshot of improved tumor 
oxygenation leading to Hif downregulation. Exogenous activation of Hifs via DMOG promoted 
exemplary facets of the hypoxic response in the absence or presence of ITPP, indicating Hif 
activity, not oxygenation as such, drives the hypoxic response. ITPP lost its impact on the 
hypoxic response and survival in the presence of DMOG, had no impact on cancer cells in vitro, 
whereas in vitro normoxia in cancer cells mimicked its in vivo effects. Therefore, the main 
action mechanism of ITPP is the provision of oxygen followed by Hif downregulation, whereas 
direct effects on cancer cells seem negligible.  
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The potent anti-hypoxic capacities of ITPP are associated with a remarkable extension of 
its effects, lasting at least a month post treatment. Vascular normalization hence is stable and 
provides opportunity for improving standard therapy. Compared to FOLFOX alone, the addition 
of ITPP prolonged survival by 2.45x, regardless whether given in overlapping or sequential 
mode. Therefore, ITPP enables functional vessel normalization that can be exploited following 
ITPP cessation. This finding provides a strong argument for the integration of ITPP into 
existing therapeutic protocols, because a sequential application (first ITPP, then chemotherapy) 
facilitates trial design and minimizes the risk of potential, harmful drug interactions. The 
estimation of clinical efficacy from animal studies remains difficult; the comparison of ITPP-
FOLFOX to the standard-of-care FOLFOX-Vegf antibody however suggests ITPP has a strong 
potential to improve clinical outcomes, albeit with the limitation that FOLFOX administration 
in mice was different from that in humans. Vegf antibody modestly enhanced FOLFOX efficacy 
(1.29x), comparable to what is known from clinical studies (32-34). Therefore, our experimental 
set up seems a clinically valid estimate of treatment effects. Under given conditions, FOLFOX-
ITPP clearly outperformed FOLFOX-Vegf antibody treatment. Our experiments were not 
designed to mechanistically explain the superiority of ITPP over Vegf inhibition. However, 
antiangiogenic therapy has its conceptual limitations (i.e. enhancement of hypoxia, targeting of 
only one aspect of the hypoxic response) and is suspected to increase metastatic risk (37, 38), 
perhaps explaining its small impact on overall survival (5, 32-34). By inhibiting the hypoxic 
response through normoxic restoration, ITPP should be largely devoid of such risks.  
A potential danger however may be ITPP administration at too wide intervals. Such 
application could lead to fluctuations in tissue O2-levels as is known from intermittent hypoxia, 
thought to be an even stronger driver of malignancy than chronic hypoxia (39). Notably, 
sufficient provision of ITPP over longer periods seems feasible. Given that ITPP acts in an 
untargeted, systemic way, the risk of resistance development likely is small compared to 
targeted agents (40, 41). More importantly, ITPP has not been associated with toxicity thus far. 
In all animals studies including ours, ITPP was very well tolerated (13-15, 42), and no impact 
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on hematological parameters has been reported (13). Minor in vitro toxicity was noted, however 
only at doses ~30x higher than we used (16). A phase Ia trial on healthy human volunteers 
(n=36) likewise concluded with an absence of drug-related adverse effects 
(http://normoxys.com/clinical-trial-results/). Indeed, ITPP even may improve the physical 
performance status (42), a relevant issue for sick and often elderly cancer patients. Side effects 
associated with antiangiogenic therapy are clearly not expected (32, 34), but how ITPP will be 
tolerated in cancer patients is unknown. A phase Ib/IIa clinical trial (NCT02528526) is currently 
addressing dosing in patients with gastrointestinal malignancy.  
In summary, we provide key information required to translate the remarkable anticancer 
effects of ITPP into the clinic. We show that ITPP efficiently inhibits various aspects associated 
with the hypoxic tumor response, including the malignant behavior of cancer cells. We 
demonstrate that the ITPP effects rely on the restoration of normoxia and the subsequent 
downregulation of Hifs, offering an action mechanism and classifying ITPP as a true 
antihypoxic compound. We further show that vascular normalization achieved through ITPP is 
stable and paralleled by a long-lasting inhibition of the hypoxic response, providing ample 
opportunity to combine with and boost the effects of current standard chemotherapy. Finally, 
we observed in a one-to-one comparison the superior performance of ITPP against neutralizing 
Vegf antibody when combined with cytotoxic regimens. Together, these findings call for a rapid 
clinical evaluation of the nontoxic, antihypoxic ITPP as a novel cancer treatment.   
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Figure Legends 
 
Figure 1. Impact of ITPP on tumor burden, hypoxia and survival in the MC-38/B6 model. A, 
General treatment schedule for ITPP. C57Bl/6 mice were portally injected with the same 
number of MC-38 cancer cells and randomly assigned to control or treatment groups upon MRI 
diagnosis on day 7. B, Tumor response towards ITPP. Analysis included tumor development 
(representative MRI scans before and after treatment, ctrl=saline control), proliferation (Ki67, 
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pH3, magnification 10x), apoptosis (caspase 3), necrosis/inflammation (serum Hmgb1), and 
tumor volume/number (pathological and MRI assessment) after treatment. C, Impact on tumoral 
Hif expression and hypoxia. Nuclear Hif1a and Hif2a expression (magnification 40x), nuclear 
and cytoplasmic Hif levels (ELISA), and pimonidazole staining for hypoxic areas 
(magnification 5x) immediately after treatment are shown. D, Kaplan-Meier survival analysis. 
Day 15 represents treatment end (n=5/group). Representative MRI scans show tumor load at 
day 45 (28 days after treatment) and at the time of death, associating death with the 
preoccupancy of the right and caudate liver lobe.  
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Figure 2. Impact of ITPP on metabolic and immune parameters in the MC-38/B6 model at day 
17. A, Impact on energy metabolism. Graphs show normalized gene expression in control 
tumors (light gray bars) and ITPP-treated tumors (dark grey bars) for glycolysis (glucose 
transporter Slc2a1, lactate dehydrogenase Ldha, mitochondrial marker Cox4i1), mitochondrial 
dynamics (mitochondrial fission Fis1 & Dsp1, mitochondrial fusion Mfn2 & Opa1), and -
oxidation genes (Cpt1a, Hadha, Hadhb).   Images (top right) show immunostaining for Cox4i1 
protein in control (ctrl) and ITPP-treated tumors (magnification 10x). B, Impact on immunity. 
Graphs to the left show normalized expression of inflammatory (upper graph; Tnfa, Il6, and 
Emr1 encoding the macrophage marker F4/80) and macrophage polarization markers (lower 
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graph; M1 markers: Cd40, Nos2a; M2 markers: Arg1, Mrc1, Mgl1). Images to the right 
(magnification 20x) show increased tumor infiltration of ITPP-treated tumors by macrophages 
(F4/80), B-cells (CD45
B220
), and NK cells (CD3).  
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Figure 3. Impact of ITPP on malignant tumor phenotype in the MC-38/B6 model at day 17. A, 
Normalized gene expression of EMT inducers (Twist, Snai1, Src), a mesenchymal marker (Vim) 
and epithelial markers (Ocln, Cdh1) in control and ITPP tumors. B, Immunohistochemistry for 
vimentin (magnification 10x/100x for upper/lower panels) in control and ITPP-treated tumors. 
Note the fibroblastoid cancer cell morphology in control tumors, and the more condensed, 
spheroid morphology in ITPP-treated tumors. C, Circulating levels of tumor-independent, 
systemic promoters of malignancy (Scf, osteopontin, Cxcl12) in control and ITPP-treated 
tumors. D, Ex vivo invasion assay on cancer cells freshly isolated from tumors immediately 
after treatment. Images show cancer cells derived from control or ITPP-treated tumors that have 
invaded through Matrigel (Boyden-chamber-assay). Invasiveness was quantified (% of cells that 
have invaded through the insert) for one tumor from each mouse (n=6/group). E, Ex vivo assay 
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for tumorigenic potential. The MRI scan shows tumor development at day 14 after s.c. injection 
of cancer cells derived from control or ITPP-treated tumors. The object in the middle represents 
the bladder. Quantification is based on the mean tumor volume from MRI scans. Cell 
suspensions were prepared from tumors of 6 mice/group and injected into 6 mice.  
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Figure 4. Impact of exogenous Hif activation on the hypoxic response and on ITPP effects. The 
Hif activator DMOG was i.v. injected 4h prior to each ITPP or saline application into B6 mice 
carrying MC-38 tumors. After treatment (day 17), hepatic gene expression and serum markers 
were analyzed. A, Hif analysis. Normalized gene (Hif1a, Hif2a, Vegfa) expression in tumors 
exposed to DMOG vehicle and saline, to DMOG and saline, to DMOG vehicle and ITPP, and to 
DMOG and ITPP. B, EMT analysis. Normalized gene expression for EMT-associated (Twist1, 
Snai1, Vim) and epithelial genes (Cdh1, Ocln). C, Analysis of circulating promoters of 
angiogenesis and metastasis. Serum Vegf, Plgf, osteopontin, Scf and Cxcl12 were quantified by 
ELISA. Note that for all parameters assessed under A-C, DMOG consistently counteracted the 
ITPP effects, with no significant difference between samples treated with saline plus vehicle 
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and samples treated with DMOG plus ITPP. D, Kaplan-Meier survival analysis. Survival count 
(6-10 mice/group) starts with treatment end (day 15, dashed line).   
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Figure 5.  Long-term impact of ITPP on hypoxic response and tumor vasculature in the MC-
38/B6 model. A, Long-term impact on the hypoxic response. Tumoral gene expression and 
serum quantifications are shown for control (-) and ITPP-treated mice (+) immediately (day 17) 
and one month (day 45) after treatment (see bottom for labels). Note the persistence of 
treatment effects for all parameters investigated. B, Long-term impact on tumor vasculature. 
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Immunohistochemistry for Cd31, Cd34, Notch1 and VE-cadherin in control and ITPP-treated 
tumors at day 45. Fading of background color was applied for better visualization of staining 
patterns. Please compare with Supplementary Fig. 6 to note the similar expression patterns 
immediately and one month after ITPP treatment.  
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Figure 6. Efficacy of ITPP treatment combined with chemotherapy versus standard-of-care 
treatment. To evaluate the efficacy of ITPP in potentiating standard chemotherapy against CRC 
liver metastases, tumor-bearing mice (the MC-38/B6 model) were treated with ITPP, FOLFOX, 
ITPP plus FOLFOX (overlapping or sequential), and FOLFOX plus Vegf antibody. A, Efficacy 
assessed by survival. Dashed line indicates treatment end. Ten mice/group were included. B, 
Efficacy assessed by tumor volume and number. MRI scans to define volume and number were 
performed immediately after treatment (day 17), four weeks after treatment (day 45) and at 
death. C, Representative MRI scans of mice treated with FOLFOX plus Vegf antibody or 
FOLFOX plus sequential ITPP. 
 
  
 29 
References 
1. Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA. Hypoxic regulation of metastasis via 
hypoxia-inducible factors. Curr Mol Med. 2008;8:60-7. 
2. Goos JA, de Cuba EM, Coupe VM, Diosdado B, Delis-Van Diemen PM, Karga C, et al. Glucose 
Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After 
Resection of Colorectal Cancer Liver Metastasis. Ann Surg 2015; 10.1097/SLA.0000000000001109. 
3. Shimomura M, Hinoi T, Kuroda S, Adachi T, Kawaguchi Y, Sasada T, et al. Overexpression of hypoxia 
inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of 
colorectal liver metastases. Ann Surg Oncol 2013;20 Suppl 3:S527-36. 
4. Van den Eynden GG, Bird NC, Majeed AW, Van Laere S, Dirix LY, Vermeulen PB. The histological 
growth pattern of colorectal cancer liver metastases has prognostic value. Clin Exp Metastasis 
2012;29:541-9. 
5. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other 
angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27. 
6. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. 
Mol Cell 2010;40:294-309. 
7. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656-65. 
8. Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in 
cancer. Cancer Res 2014;74:7185-90. 
9. Jiang J, Tang YL, Liang XH. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol 
Ther 2011;11:714-23. 
10. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer 
stem cells. Br J Cancer 2010;102:789-95. 
11. Fylaktakidou KC, Lehn JM, Greferath R, Nicolau C. Inositol tripyrophosphate: a new membrane 
permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett 2005;15:1605-8. 
12. Duarte CD, Greferath R, Nicolau C, Lehn JM. myo-Inositol trispyrophosphate: a novel allosteric 
effector of hemoglobin with high permeation selectivity across the red blood cell plasma 
membrane. Chembiochem 2010;11:2543-8. 
13. Aprahamian M, Bour G, Akladios CY, Fylaktakidou K, Greferath R, Soler L, et al. Myo-
InositolTrisPyroPhosphate treatment leads to HIF-1alpha suppression and eradication of early 
hepatoma tumors in rats. Chembiochem 2011;12:777-83. 
14. Derbal-Wolfrom L, Pencreach E, Saandi T, Aprahamian M, Martin E, Greferath R, et al. Increasing the 
oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and 
modulates the intestine homeobox gene Cdx2. Oncogene 2013;32:4313-8. 
15. Kieda C, El Hafny-Rahbi B, Collet G, Lamerant-Fayel N, Grillon C, Guichard A, et al. Stable tumor 
vessel normalization with pO(2) increase and endothelial PTEN activation by inositol 
trispyrophosphate brings novel tumor treatment. J Mol Med 2013;91:883-99. 
16. Raykov Z, Grekova SP, Bour G, Lehn JM, Giese NA, Nicolau C, et al. Myo-inositol trispyrophosphate-
mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine 
efficacy. Int J Cancer 2014;134:2572-82. 
17. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: 
a population-based study. Cancer 2007;109:718-26. 
18. Eckle T, Brodsky K, Bonney M, Packard T, Han J, Borchers CH, et al. HIF1A reduces acute lung injury 
by optimizing carbohydrate metabolism in the alveolar epithelium. PLoS Biol 2013;11:e1001665. 
19. Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, et al. Pathogenesis of FOLFOX 
induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hep 2013;59:318-26. 
20. Oberkofler CE, Limani P, Jang JH, Rickenbacher A, Lehmann K, Raptis DA, et al. Systemic protection 
through remote ischemic preconditioning is spread by platelet-dependent signaling in mice. 
Hepatology 2014;60:1409-17. 
21. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, et al. Serotonin regulates macrophage-
mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res 2008;68:5152-8. 
22. Shaw LM. Tumor cell invasion assays. Meth Mol Biol 2005;294:97-105. 
23. Dubey P, Shrivastava R, Tripathi C, Jain NK, Tewari BN, Lone MU, et al. Cyclooxygenase-2 inhibition 
attenuates hypoxic cancer cells induced M2-polarization of macrophages. Cell Mol Biol 2014;60:10-
5. 
 30 
24. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors 
induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl 
Acad Sci USA 2007;104:17069-74. 
25. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the 
von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 
2001;292:468-72. 
26. Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A, et al. Hypoxia-driven osteopontin 
contributes to breast tumor growth through modulation of HIF1alpha-mediated VEGF-dependent 
angiogenesis. Oncogene 2014;33:2053-64. 
27. Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, et al. Tumor vessel normalization by 
chloroquine independent of autophagy. Cancer Cell 2014;26:190-206. 
28. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, et al. Heterozygous 
deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial 
normalization. Cell 2009;136:839-51. 
29. Agrawal V, Maharjan S, Kim K, Kim NJ, Son J, Lee K, et al. Direct endothelial junction restoration 
results in significant tumor vascular normalization and metastasis inhibition in mice. Oncotarget 
2014;5:2761-77. 
30. Dill MT, Rothweiler S, Djonov V, Hlushchuk R, Tornillo L, Terracciano L, et al. Disruption of Notch1 
induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. 
Gastroenterology 2012;142:967-77 e2. 
31. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-
dependent endocytosis of VE-cadherin. Nat Cell Biol 2006;8:1223-34. 
32. Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, et al. Effectiveness of bevacizumab 
added to standard chemotherapy in metastatic colorectal cancer: final results for first-line 
treatment from the ITACa randomized clinical trial. Ann Oncol 2015;26:1201-7. 
33. Chen YX, Yang Q, Kuang JJ, Chen SY, Wei Y, Jiang ZM, et al. Efficacy of adding bevacizumab in the 
first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical 
trials. Gastroenterol Res Pract 2014;2014:594930. 
34. Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in 
advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on 
chemotherapy subgroups. BMC Cancer 2012;12:89. 
35. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, et al. HRG inhibits tumor growth and 
metastasis by inducing macrophage polarization and vessel normalization through downregulation 
of PlGF. Cancer Cell 2011;19:31-44. 
36. Qin T, Wang C, Chen X, Duan C, Zhang X, Zhang J, et al. Dopamine induces growth inhibition and 
vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma. Toxicol 
Appl Pharmacol 2015;286:112-23. 
37. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits 
malignant progression of tumors to increased local invasion and distant metastasis. Cancer cell. 
2009;15:220-31. 
38. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis 
after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-
9. 
39. Dewhirst MW. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. 
Cancer Res 2007;67:854-5. 
40. Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Kirkpatrick ND, et al. Effects of vascular-
endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic 
progression. J Natl Cancer Inst 2013;105:1188-201. 
41. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49. 
42. Biolo A, Greferath R, Siwik DA, Qin F, Valsky E, Fylaktakidou KC, et al. Enhanced exercise capacity in 
mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol 
trispyrophosphate. Proc Natl Acad Sci USA 2009;106:1926-9. 
 
